|
1.
|
Parkin DM, Bray F, Ferlay J and Pisani P:
Estimating the world cancer burden: Globocan 2000. Int J Cancer.
94:153–156. 2001. View
Article : Google Scholar : PubMed/NCBI
|
|
2.
|
Perz JF, Armstrong GL, Farrington LA,
Hutin YJ and Bell BP: The contributions of hepatitis B virus and
hepatitis C virus infections to cirrhosis and primary liver cancer
worldwide. J Hepatol. 45:529–538. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
3.
|
Tanaka K, Hirohata T, Takeshita S,
Hirohata I, Koga S, Sugimachi K, Kanematsu T, Ohryohji F and
Ishibashi H: Hepatitis B virus, cigarette smoking and alcohol
consumption in the development of hepatocellular carcinoma: a
case-control study in Fukuoka, Japan. Int J Cancer. 51:509–514.
1992. View Article : Google Scholar : PubMed/NCBI
|
|
4.
|
Bosch FX, Ribes J, Cleries R and Diaz M:
Epidemiology of hepatocellular carcinoma. Clin Liver Dis.
9:191–211. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
5.
|
El-Serag HB: Hepatocellular carcinoma:
recent trends in the United States. Gastroenterology. 127:S27–S34.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
6.
|
Sherman M: Hepatocellular carcinoma:
epidemiology, risk factors, and screening. Semin Liver Dis.
25:143–154. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
7.
|
Park NH, Song IH and Chung YH: Chronic
hepatitis B in hepatocarcinogenesis. Postgrad Med J. 82:507–515.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
8.
|
Chau GY, Wu CW, Lui WY, Chang TJ, Kao HL,
Wu LH, King KL, Loong CC, Hsia CY and Chi CW: Serum interleukin-10
but not interleukin-6 is related to clinical outcome in patients
with resectable hepatocellular carcinoma. Ann Surg. 231:552–558.
2000. View Article : Google Scholar : PubMed/NCBI
|
|
9.
|
Hsu YC, Fu HH, Jeng YM, Lee PH and Yang
SD: Proline-directed protein kinase FA is a powerful and
independent prognostic predictor for progression and patient
survival of hepatocellular carcinoma. J Clin Oncol. 24:3780–3788.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
10.
|
Kitamoto M, Nakanishi T, Kira S, Kawaguchi
M, Nakashio R, Suemori S, Kajiyama G, Asahara T and Dohi K: The
assessment of proliferating cell nuclear antigen
immunohistochemical staining in small hepatocellular carcinoma and
its relationship to histologic characteristics and prognosis.
Cancer. 72:1859–1865. 1993. View Article : Google Scholar
|
|
11.
|
Kobayashi T, Kubota K, Takayama T and
Makuuchi M: Telomerase activity as a predictive marker for
recurrence of hepatocellular carcinoma after hepatectomy. Am J
Surg. 181:284–288. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
12.
|
Poon RT, Lau CP, Ho JW, Yu WC, Fan ST and
Wong J: Tissue factor expression correlates with tumor angiogenesis
and invasiveness in human hepatocellular carcinoma. Clin Cancer
Res. 9:5339–5345. 2003.PubMed/NCBI
|
|
13.
|
Poon RT, Ng IO, Lau C, Zhu LX, Yu WC, Lo
CM, Fan ST and Wong J: Serum vascular endothelial growth factor
predicts venous invasion in hepatocellular carcinoma: a prospective
study. Ann Surg. 233:227–235. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
14.
|
Shen HM and Ong CN: Mutations of the p53
tumor suppressor gene and ras oncogenes in aflatoxin
hepatocarcinogenesis. Mutat Res. 366:23–44. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
15.
|
Tsujita E, Taketomi A, Gion T, Kuroda Y,
Endo K, Watanabe A, Nakashima H, Aishima S, Kohnoe S and Maehara Y:
Suppressed MKP-1 is an independent predictor of outcome in patients
with hepatocellular carcinoma. Oncology. 69:342–347. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
16.
|
Uenishi T, Kubo S, Yamamoto T, Shuto T,
Ogawa M, Tanaka H, Tanaka S, Kaneda K and Hirohashi K: Cytokeratin
19 expression in hepatocellular carcinoma predicts early
postoperative recurrence. Cancer Sci. 94:851–857. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
17.
|
Lee TK, Poon RT, Yuen AP, Ling MT, Kwok
WK, Wang XH, Wong YC, Guan XY, Man K, Chau KL and Fan ST: Twist
over-expression correlates with hepatocellular carcinoma metastasis
through induction of epithelial-mesenchymal transition. Clin Cancer
Res. 12:5369–5376. 2006. View Article : Google Scholar
|
|
18.
|
Zhu K, Dai Z, Pan Q, Wang Z, Yang GH, Yu
L, Ding ZB, Shi GM, Ke AW, Yang XR, Tao ZH, Zhao YM, Qin Y, Zeng
HY, Tang ZY, Fan J and Zhou J: Metadherin promotes hepatocellular
carcinoma metastasis through induction of epithelial-mesenchymal
transition. Clin Cancer Res. 17:7294–7302. 2011. View Article : Google Scholar
|
|
19.
|
Eisen MB, Spellman PT, Brown PO and
Botstein D: Cluster analysis and display of genome-wide expression
patterns. Proc Natl Acad Sci USA. 95:14863–14868. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
20.
|
Saldanha AJ: Java Treeview - extensible
visualization of micro-array data. Bioinformatics. 20:3246–3248.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
21.
|
Mazumdar M and Glassman JR: Categorizing a
prognostic variable: review of methods, code for easy
implementation and applications to decision-making about cancer
treatments. Stat Med. 19:113–132. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
22.
|
Trevisani F, Cantarini MC, Wands JR and
Bernardi M: Recent advances in the natural history of
hepatocellular carcinoma. Carcinogenesis. 29:1299–1305. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
23.
|
Chen R, Yang Q and Lee JD: BMK1 kinase
suppresses epithelialmesenchymal transition through the
Akt/GSK3beta signaling pathway. Cancer Res. 72:1579–1587. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
24.
|
Fenouille N, Tichet M, Dufies M, Pottier
A, Mogha A, Soo JK, Rocchi S, Mallavialle A, Galibert MD, Khammari
A, Lacour JP, Ballotti R, Deckert M and Tartare-Deckert S: The
epithelialmesenchymal transition (EMT) regulatory factor SLUG
(SNAI2) is a downstream target of SPARC and AKT in promoting
melanoma cell invasion. PLoS One. 7:e403782012. View Article : Google Scholar : PubMed/NCBI
|
|
25.
|
Jiao M and Nan KJ: Activation of PI3
kinase/Akt/HIF-1alpha pathway contributes to hypoxia-induced
epithelial-mesenchymal transition and chemoresistance in
hepatocellular carcinoma. Int J Oncol. 40:461–468. 2012.PubMed/NCBI
|
|
26.
|
Maseki S, Ijichi K, Tanaka H, Fujii M,
Hasegawa Y, Ogawa T, Murakami S, Kondo E and Nakanishi H:
Acquisition of EMT phenotype in the gefitinib-resistant cells of a
head and neck squamous cell carcinoma cell line through
Akt/GSK-3beta/snail signalling pathway. Br J Cancer. 106:1196–1204.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
27.
|
Ogunwobi OO and Liu C: Hepatocyte growth
factor upregulation promotes carcinogenesis and
epithelial-mesenchymal transition in hepatocellular carcinoma via
Akt and COX-2 pathways. Clin Exp Metastasis. 28:721–731. 2011.
View Article : Google Scholar
|
|
28.
|
Ogunwobi OO, Wang T, Zhang L and Liu C:
Cyclooxygenase-2 and Akt mediate multiple growth-factor-induced
epithelialmesenchymal transition in human hepatocellular carcinoma.
J Gastroenterol Hepatol. 27:566–578. 2012. View Article : Google Scholar
|
|
29.
|
Wen W, Ding J, Sun W, Fu J, Chen Y, Wu K,
Ning B, Han T, Huang L, Chen C, Xie D, Li Z, Feng G, Wu M, Xie W
and Wang H: Cyclin G1-mediated epithelial-mesenchymal transition
via phosphoinositide 3-kinase/Akt signaling facilitates liver
cancer progression. Hepatology. 55:1787–1798. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
30.
|
Frese S, Pirnia F, Miescher D, Krajewski
S, Borner MM, Reed JC and Schmid RA: PG490-mediated sensitization
of lung cancer cells to Apo2L/TRAIL-induced apoptosis requires
activation of ERK2. Oncogene. 22:5427–5435. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
31.
|
Liang X, Du J, Liu Y, Cui M, Ma C, Han L,
Qu Z, Zhang Z, Sun Z, Zhang L, Chen YH and Sun W: The hepatitis B
virus protein MHBs(t) sensitizes hepatoma cells to TRAIL-induced
apoptosis through ERK2. Apoptosis. 12:1827–1836. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
32.
|
Bakarakos P, Theohari I, Nomikos A, Mylona
E, Papadimitriou C, Dimopoulos AM and Nakopoulou L:
Immunohistochemical study of PTEN and phosphorylated mTOR proteins
in familial and sporadic invasive breast carcinomas.
Histopathology. 56:876–882. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
33.
|
Hirashima K, Baba Y, Watanabe M, Karashima
R, Sato N, Imamura Y, Hiyoshi Y, Nagai Y, Hayashi N, Iyama K and
Baba H: Phosphorylated mTOR expression is associated with poor
prognosis for patients with esophageal squamous cell carcinoma. Ann
Surg Oncol. 17:2486–2493. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
34.
|
Li N, Zhong M and Song M: Expression of
phosphorylated mTOR and its regulatory protein is related to
biological behaviors of ameloblastoma. Int J Clin Exp Pathol.
5:660–667. 2012.PubMed/NCBI
|
|
35.
|
Ueng SH, Chen SC, Chang YS, Hsueh S, Lin
YC, Chien HP, Lo YF, Shen SC and Hsueh C: Phosphorylated mTOR
expression correlates with poor outcome in early-stage triple
negative breast carcinomas. Int J Clin Exp Pathol. 5:806–813.
2012.PubMed/NCBI
|
|
36.
|
Yoshida Y, Kurokawa T, Horiuchi Y,
Sawamura Y, Shinagawa A and Kotsuji F: Localisation of
phosphorylated mTOR expression is critical to tumour progression
and outcomes in patients with endometrial cancer. Eur J Cancer.
46:3445–3452. 2010. View Article : Google Scholar : PubMed/NCBI
|
